Jiyun Shi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1062894/publications.pdf

Version: 2024-02-01

236925 276875 1,769 44 25 41 citations h-index g-index papers 46 46 46 2028 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	A novel peptide-based probe 99mTc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. Chinese Chemical Letters, 2022, 33, 3497-3501.	9.0	2
2	Palmitic Acid-Conjugated Radiopharmaceutical for Integrin $\hat{l}\pm v\hat{l}^2$ 3-Targeted Radionuclide Therapy. Pharmaceutics, 2022, 14, 1327.	4.5	3
3	A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer. International Journal of Nanomedicine, 2021, Volume 16, 3185-3199.	6.7	13
4	An Integrin- \hat{l} ± \langle sub \rangle v \langle /sub \rangle \hat{l} 2 \langle sub \rangle 6 \langle /sub \rangle 1 \langle /sub \rangle 1 \langle /sub \rangle -Bitargeted Probe for the SPECT Imaging of Pancreatic Adenocarcinoma in Preclinical and Primary Clinical Studies. Bioconjugate Chemistry, 2021, 32, 1298-1305.	3.6	5
5	Monoclonal-Antibody-Templated Gold Nanoclusters for HER2 Receptors Targeted Fluorescence Imaging. ACS Applied Bio Materials, 2020, 3, 7061-7066.	4.6	11
6	Developing PEGylated Reversed D-Peptide as a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection. Bioconjugate Chemistry, 2020, 31, 1971-1980.	3.6	18
7	Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. , 2020, 8, e001156.		31
8	High Intensity Focused Ultrasound-Responsive and Ultrastable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial–Mesenchymal Transition. ACS Nano, 2020, 14, 15904-15918.	14.6	63
9	Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2613-2623.	6.4	15
10	A ⁶⁴ Cuâ€porphyrinâ€based dualâ€modal molecular probe with integrin α _v β ₃ targeting function for tumour imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 212-221.	1.0	13
11	Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agent. Nature Communications, 2020, 11, 567.	12.8	66
12	An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake. Bioconjugate Chemistry, 2020, 31, 1510-1521.	3.6	10
13	Host–Guest Polypyrrole Nanocomplex for Threeâ€Stimuliâ€Responsive Drug Delivery and Imagingâ€Guided Chemoâ€Photothermal Synergetic Therapy of Refractory Thyroid Cancer. Advanced Healthcare Materials, 2019, 8, e1900661.	7.6	34
14	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 2019, 10, 3874.	12.8	132
15	Improved in Vivo Targeting Capability and Pharmacokinetics of ^{99m} Tc-Labeled isoDGR by Dimerization and Albumin-Binding for Glioma Imaging. Bioconjugate Chemistry, 2019, 30, 2038-2048.	3.6	18
16	Small-animal SPECT/CT imaging of cancer xenografts and pulmonary fibrosis using a 99mTc-labeled integrin αvβ6-targeting cyclic peptide with improved in vivo stability. Biophysics Reports, 2018, 4, 254-264.	0.8	14
17	Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts. Oncotarget, 2017, 8, 6364-6375.	1.8	6
18	SPECT/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon Tumor with an Avidin/Biotin Pretargeting System. Scientific Reports, 2016, 6, 18905.	3.3	24

#	Article	IF	CITATIONS
19	$sup>99mTc-HisoDGR$ as a Potential SPECT Probe for Orthotopic Glioma Detection via Targeting of Integrin $\hat{l}\pm sub>5\hat{l}^2 sub>1$. Bioconjugate Chemistry, 2016, 27, 1259-1266.	3.6	25
20	Integrin Imaging with sup>99m sysup>Tc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non†Small Cell Lung Cancer. Radiology, 2016, 281, 958-966.	7.3	34
21	Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophysics Reports, 2016, 2, 1-20.	0.8	64
22	Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin α _v β ₃ â€"targeting Radiotracer. Radiology, 2016, 279, 502-512.	7.3	26
23	Polymer–Doxorubicin Conjugate Micelles Based on Poly(ethylene glycol) and Poly(<i>N</i> -(2-hydroxypropyl) methacrylamide): Effect of Negative Charge and Molecular Weight on Biodistribution and Blood Clearance. Biomacromolecules, 2015, 16, 2645-2655.	5.4	26
24	⁶⁸ Ga-Labeled 3PRGD ₂ for Dual PET and Cerenkov Luminescence Imaging of Orthotopic Human Glioblastoma. Bioconjugate Chemistry, 2015, 26, 1054-1060.	3.6	22
25	¹⁷⁷ Lu-Labeled Cerasomes Encapsulating Indocyanine Green for Cancer Theranostics. ACS Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics and Applied Materials & Description of the Cancer Theranostics & Description of the Cancer Therano	8.0	39
26	Anti-tumor Effect of Integrin Targeted ¹⁷⁷ Lu-3PRGD ₂ and Combined Therapy with Endostar. Theranostics, 2014, 4, 256-266.	10.0	25
27	Integrin α _v β ₆ –Targeted SPECT Imaging for Pancreatic Cancer Detection. Journal of Nuclear Medicine, 2014, 55, 989-994.	5.0	50
28	PET Imaging of Neovascularization with ⁶⁸ Ga-3PRGD ₂ for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy. Molecular Pharmaceutics, 2014, 11, 3915-3922.	4.6	27
29	Synthesis of poly(ethylene glycol)-b-poly(N-(2-hydroxypropyl) methacrylamide) block copolymers with well-defined structures and their influence on in vivo circulation and biodistribution. Polymer Chemistry, 2014, 5, 5617-5627.	3.9	18
30	Technetium 99m-labeled VQ peptide: a new imaging agent for the early detection of tumors or premalignancies. Molecular Imaging, 2013, 12, 318-26.	1.4	0
31	^{99m} Tc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study. Journal of Nuclear Medicine, 2012, 53, 716-722.	5.0	112
32	Two ⁹⁰ Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy. Molecular Pharmaceutics, 2011, 8, 591-599.	4.6	36
33	Evaluation of ¹¹¹ In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics, 2011, 1, 322-340.	10.0	47
34	Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin $\hat{l}\pm v\hat{l}^2$ 3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates. Molecular Imaging and Biology, 2011, 13, 730-736.	2.6	69
35	Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers. Amino Acids, 2011, 41, 1059-1070.	2.7	27
36	Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer. Amino Acids, 2010, 39, 111-120.	2.7	18

#	Article	IF	CITATION
37	Evaluation of ¹¹¹ In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent. Bioconjugate Chemistry, 2010, 21, 969-978.	3.6	51
38	99mTcO(MAG2-3G3-dimer): a new integrin $\hat{l}\pm v\hat{l}^2$ 3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1874-1884.	6.4	42
39	Improving Tumor-Targeting Capability and Pharmacokinetics of ^{99m} Tc-Labeled Cyclic RGD Dimers with PEG ₄ Linkers. Molecular Pharmaceutics, 2009, 6, 231-245.	4.6	136
40	2-Mercaptoacetylglycylglycyl (MAG ₂) as a Bifunctional Chelator for ^{99m} Tc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjugate Chemistry, 2009, 20, 1559-1568.	3.6	34
41	Improving Tumor Uptake and Pharmacokinetics of 64Cu-Labeled Cyclic RGD Peptide Dimers with Gly3and PEG4Linkers. Bioconjugate Chemistry, 2009, 20, 750-759.	3.6	123
42	^{99m} Tc-Labeled Bombesin(7â^'14)NH ₂ with Favorable Properties for SPECT Imaging of Colon Cancer. Bioconjugate Chemistry, 2008, 19, 1170-1178.	3.6	44
43	Improving Tumor Uptake and Excretion Kinetics of ⁹⁹ ^m Tc-Labeled Cyclic Arginine-Glycine-Aspartic (RGD) Dimers with Triglycine Linkers. Journal of Medicinal Chemistry, 2008, 51, 7980-7990.	6.4	115
44	99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3Expression. Bioconjugate Chemistry, 2006, 17, 1069-1076.	3.6	65